Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.

Breast Cancer Res Treat · 2012 · PMC3397230 · PMID 22270930

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Considering that a subtype of breast cancers is categorized by HER2/neu positive and expression of HER2/neu predicts poor outcome in patients, association of HER2/neu with Ecd is highly significant and could serve as a marker for poor outcome of patients.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.